Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + Cisplatin in Malignant Pleural Mesothelioma
NCT00251550Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in malignant pleural mesothelioma (MPM), sponsored by Eli Lilly and Company. Primary endpoints: Recommended dose of LY231514 and cisplatin combination therapy and Response Rate. Started Oct 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT00251550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251550.